Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 mars 2026 10h57 HE | Source: FemPulse

FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference

SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal...
21 janv. 2026 09h46 HE | Source: Research and Markets

New Market Intelligence Report Illuminates Growth Opportunities in the Global Nocturnal Enuresis Market

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Nocturnal Enuresis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ...
08 juil. 2025 09h15 HE | Source: Research and Markets

Nocturia Market Research and Forecast Report 2025-2034, Featuring Leading Players - Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie, Teva Pharmaceuticals

Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Nocturia Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering. The nocturia market is set to experience robust...
07 avr. 2025 10h11 HE | Source: FemiPro

FemiPro: Introducing FemiPro as the Bizarre Bladder Strengthening Hack for Urinary Incontinence Support

TALLMADGE, Ohio, April 07, 2025 (GLOBE NEWSWIRE) -- FemiPro emerges at a pivotal moment in women’s health. Millions of women quietly endure urinary incontinence – from frequent bathroom trips to...
11 déc. 2024 15h18 HE | Source: FemPulse

FemPulse Receives FDA IDE Approval for the Pivotal Clinical Trial of its Wearable Bioelectronic Device for Overactive Bladder in Women

SAN FRANCISO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II...
30 avr. 2024 05h36 HE | Source: Research and Markets

Global Urology Supplements Market Trends Analysis Report 2024-2030: Asia Pacific Emerges as Dominant Force, Multi-Ingredient Supplements Lead

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Global Urology Supplements Market Size, Share & Trends Analysis Report by Type (Multi-ingredient, Single Ingredient), Application (Urinary Tract...
04 janv. 2024 08h00 HE | Source: EG 427

EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)

EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In a non-clinical pharmacology study in an OAB model,...
20 sept. 2023 12h00 HE | Source: STIMVIA s.r.o.

STIMVIA Unveils Innovative Solution to Transform CNS Disorder Treatments at TechCrunch Disrupt 2023

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- STIMVIA, a pioneer medical technology company, introduces an effective non-invasive neuromodulation treatment, URIS®, addressing deep brain...
13 juil. 2023 02h00 HE | Source: EG 427

EG 427 announces final Series A closing, achieving €18 million in total funds raised

Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an...
02 mai 2023 08h00 HE | Source: Elidah Inc.

Women’s Health Leader Elidah Launches Game-changing ELITONE URGE Device To Treat Overactive Bladder

MONROE, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- Providing the same relief for overactive bladder (OAB) that they’ve become known for in the stress urinary incontinence arena, MedTech Elidah is...

Page suivante